Extended Follow-up of Patients with Melanoma Treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from Study R3767-ONC-1613
The purpose of this study is to obtain long-term data for disease response, overall survival (OS), and progression-free survival (PFS), and the subsequent use of anti-cancer treatments in patients with melanoma, who had previously been treated with fianlimab and cemiplimab.
Why this Research Matters
This is a phase 2 extended follow-up study of patients with melanoma who had previously been treated with the combination of fianlimab and cemiplimab in expansion cohorts 6, 15, and 16 in the R3767-ONC-1613 study.
Who can Participate
Adult
Participants with melanoma who enrolled in cohorts 6, 15, or 16 of study R3767-ONC- 1613.
Study ID
Protocol Number: 25-0931
More information available at ClinicalTrials.gov: NCT06848088
Meet the Team
Principal Investigator